Filing Details

Accession Number:
0000880771-17-000069
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-04-28 17:49:55
Reporting Period:
2017-04-26
Filing Date:
2017-04-28
Accepted Time:
2017-04-28 17:49:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
880771 Sciclone Pharmaceuticals Inc SCLN Pharmaceutical Preparations (2834) 943116852
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1363213 Friedhelm Blobel 950 Tower Lane, Suite 900
Foster City CA 94404
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-04-26 1,400 $3.55 93,926 No 4 M Direct
Common Stock Disposition 2017-04-26 1,400 $10.00 92,526 No 4 S Direct
Common Stock Acquisiton 2017-04-27 2,800 $3.55 95,326 No 4 M Direct
Common Stock Disposition 2017-04-27 2,800 $10.01 92,526 No 4 S Direct
Common Stock Acquisiton 2017-04-28 200 $3.55 92,726 No 4 M Direct
Common Stock Disposition 2017-04-28 200 $10.00 92,526 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2017-04-26 1,400 $0.00 1,400 $3.55
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2017-04-27 2,800 $0.00 2,800 $3.55
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2017-04-28 200 $0.00 200 $3.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
209,000 2020-03-05 No 4 M Direct
206,200 2020-03-05 No 4 M Direct
206,000 2020-03-05 No 4 M Direct
Footnotes
  1. The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
  2. Granted under the Issuer's 2005 Equity Incentive Plan.
  3. 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.